Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study.

[1]  K. St. George,et al.  Cytomegalovirus PP65 antigenemia monitoring as a guide for preemptive therapy: a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients. , 1999, Transplantation.

[2]  R. Busuttil,et al.  Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors. , 1997, Transplantation.

[3]  M. Pescovitz,et al.  Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients , 1997, The Lancet.

[4]  D. Snydman,et al.  The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. , 1997, The American journal of medicine.

[5]  R. Wiesner,et al.  Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database. , 1997, Transplantation.

[6]  D. Snydman,et al.  Effect of Cytomegalovirus Infection Status on First-Year Mortality Rates among Orthotopic Liver Transplant Recipients , 1997, Annals of Internal Medicine.

[7]  J. Rabkin,et al.  Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation. , 1997, Transplantation.

[8]  D. Snydman,et al.  Cytomegalovirus prophylaxis in solid organ transplant recipients. , 1996, Transplantation.

[9]  D. Snydman,et al.  Preemptive Ganciclovir Therapy To Prevent Cytomegalovirus Disease in Cytomegalovirus Antibody-Positive Renal Transplant Recipients , 1995, Annals of Internal Medicine.

[10]  J. Oundo,et al.  Simultaneous outbreak due to Vibrio cholerae and Shigella dysenteriae in Kenya , 1995, The Lancet.

[11]  T. Starzl,et al.  A PROSPECTIVE RANDOMIZED TRIAL COMPARING SEQUENTIAL GANCICLOVIR‐HIGH DOSE ACYCLOVIR TO HIGH DOSE ACYCLOVIR FOR PREVENTION OF CYTOMEGALOVIRUS DISEASE IN ADULT LIVER TRANSPLANT RECIPIENTS , 1994, Transplantation.

[12]  M. Samore,et al.  Risk factors for invasive fungal infections complicating orthotopic liver transplantation. , 1994, The Journal of infectious diseases.

[13]  Nina Singh,et al.  High-Dose Acyclovir Compared with Short-Course Preemptive Ganciclovir Therapy To Prevent Cytomegalovirus Disease in Liver Transplant Recipients , 1994, Annals of Internal Medicine.

[14]  J. Aguado,et al.  Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies , 1993, Antimicrobial Agents and Chemotherapy.

[15]  T. F. Smith,et al.  Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. , 1993, Journal of hepatology.

[16]  D. Snydman,et al.  Final analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus-immune globulin: comparison of the randomized and open-label trials. , 1991, Transplantation proceedings.

[17]  R. Rubin,et al.  Combined antibody and ganciclovir treatment of murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice , 1989, Antimicrobial Agents and Chemotherapy.

[18]  D. Stover,et al.  Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. , 1988, Annals of internal medicine.

[19]  M. Goormastic,et al.  Symptomatic cytomegalovirus infection as a significant risk factor for major infections after cardiac transplantation. , 1988, The Journal of infectious diseases.